CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
CARGO Therapeutics (NASDAQ: CRGX), a clinical-stage biotech company focused on developing next-generation cell therapies for cancer patients, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place from January 13-16, 2025, in San Francisco, California.
President and CEO Gina Chapman will deliver a presentation on Monday, January 13, at 10:30 a.m. PT. The presentation will be accessible via live webcast in the Investors section of CARGO's website under News & Events, with a replay available for approximately 30 days following the presentation.
CARGO Therapeutics (NASDAQ: CRGX), un'azienda biotech in fase clinica focalizzata sullo sviluppo di terapie cellulari di nuova generazione per pazienti affetti da cancro, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. La conferenza si svolgerà dal 13 al 16 gennaio 2025 a San Francisco, California.
Il Presidente e CEO Gina Chapman terrà una presentazione lunedì 13 gennaio, alle 10:30 PT. La presentazione sarà accessibile tramite webcast dal vivo nella sezione Investitori del sito di CARGO, sotto Notizie ed Eventi, con una riproduzione disponibile per circa 30 giorni dopo la presentazione.
CARGO Therapeutics (NASDAQ: CRGX), una empresa biotecnológica en etapa clínica centrada en desarrollar terapias celulares de próxima generación para pacientes con cáncer, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. La conferencia se llevará a cabo del 13 al 16 de enero de 2025, en San Francisco, California.
La Presidenta y CEO Gina Chapman realizará una presentación el lunes 13 de enero, a las 10:30 a.m. PT. La presentación será accesible a través de una transmisión web en vivo en la sección de Inversores del sitio web de CARGO, bajo Noticias y Eventos, con una repetición disponible durante aproximadamente 30 días después de la presentación.
CARGO Therapeutics (NASDAQ: CRGX), 임상 단계의 생명공학 회사로서 암 환자를 위한 차세대 세포 치료법 개발에 집중하고 있는 회사가 제43회 JP모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 이 컨퍼런스는 2025년 1월 13일부터 16일까지 샌프란시스코, 캘리포니아에서 개최됩니다.
CEO인 지나 채프먼이 1월 13일 월요일, 오전 10시 30분 PT에 발표를 진행할 예정입니다. 발표는 CARGO 웹사이트의 투자자 섹션의 뉴스 및 이벤트에서 실시간 웹캐스트를 통해 접근할 수 있으며, 발표 후 약 30일 동안 재생이 가능합니다.
CARGO Therapeutics (NASDAQ: CRGX), une entreprise de biotechnologie en phase clinique spécialisée dans le développement de thérapies cellulaires de nouvelle génération pour les patients atteints de cancer, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. La conférence se tiendra du 13 au 16 janvier 2025, à San Francisco, Californie.
La Présidente et CEO Gina Chapman fera une présentation le lundi 13 janvier, à 10h30 PT. La présentation sera accessible via un webinaire en direct dans la section Investisseurs du site de CARGO, sous Actualités & Événements, avec un replay disponible pendant environ 30 jours après la présentation.
CARGO Therapeutics (NASDAQ: CRGX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Zelltherapien der nächsten Generation für Krebspatienten konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Die Konferenz findet vom 13. bis 16. Januar 2025 in San Francisco, Kalifornien, statt.
Die Präsidentin und CEO Gina Chapman wird am Montag, den 13. Januar, um 10:30 Uhr PT eine Präsentation halten. Die Präsentation wird über einen Live-Webcast im Investorenbereich der CARGO-Website unter Nachrichten & Veranstaltungen zugänglich sein, mit einer Wiederholung, die etwa 30 Tage nach der Präsentation verfügbar sein wird.
- None.
- None.
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California.
Gina Chapman, President and Chief Executive Officer, is scheduled to present on Monday, January 13, at 10:30 a.m. PT.
Interested parties can access the live webcast for the presentation in the Investors section of CARGO’s website under News & Events. A replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.
About CARGO Therapeutics
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next- generation, potentially curative cell therapies for cancer patients. CARGO’s programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply. CARGO is currently evaluating firicabtagene autoleucel (firi-cel), an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical study in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. CARGO has developed proprietary cell engineering platform technologies which it leverages to develop a pipeline of programs that incorporate multiple transgene therapeutic “cargo” designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion. This includes the CRG-023 program, which incorporates a novel tri-specific CAR T with CD2 co-stimulation that is designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a broad range of B-cell malignancies with the goal of providing more patients with a durable complete response. CARGO’s leadership and team have significant experience in developing, engineering, manufacturing, and commercializing oncology and cell therapy products. For more information, please visit the CARGO Therapeutics website at https://cargo-tx.com/.
Follow us on LinkedIn: CARGO Therapeutics
Follow us on X (Twitter): @CARGOTx
Contacts
Media Contact:
Kimberly Muscara
kimberly@redhousecomms.com
Investor Contact:
Jessica Serra
jserra@cargo-tx.com
Laurence Watts
laurence@newstreetir.com
FAQ
When is CARGO Therapeutics (CRGX) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch CARGO Therapeutics' (CRGX) J.P. Morgan Healthcare Conference presentation?
What is CARGO Therapeutics' (CRGX) main focus as a company?
How long will the replay of CRGX's J.P. Morgan Healthcare Conference presentation be available?
